Open Access<p>Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer</p>
Author(s) -
Chengtao Sun,
Liping Zhang,
Wei Zhang,
Yü Liu,
Bin Chen,
Sha Zhao,
Wei Li,
Lei Wang,
Lingyun Ye,
Keyi Jia,
Hao Wang,
Chunyan Wu,
Yayi He,
Caicun Zhou
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s252031
Subject(s) - tumor infiltrating lymphocytes , pd l1 , foxp3 , cd8 , immunohistochemistry , medicine , lung cancer , immune system , cd3 , tumor microenvironment , cancer research , oncology , immunology , immunotherapy
Immune therapy has shown good results in small-cell lung cancer (SCLC), but the impact of immune microenvironment of the disease is unclear. In this work, we detected expression of programmed death 1 (PD-1), PD-ligand 1 (PD-L1), and other immune biomarkers of cancer. We also analyzed the correlations between these markers and survival in SCLC.